Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 788 (110th)

Food and Drug Administration Safety Act of 2007

referredUnited States· United States Congress· EN

Introduced

31 January 2007

Last action

2 February 2007 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Tierney, John F. [D-MA-6], Rep. Ramstad, Jim [R-MN-3], Rep. Miller, George [D-CA-11], Rep. Clay, Wm. Lacy [D-MO-1], James McGovern, Rep. Davis, Danny K. [D-IL-7]

Subjects

Healthcare

Source updated

5 December 2025

Healthcare

Summary

Food and Drug Administration Safety Act of 2007 - Amends the Federal Food, Drug, and Cosmetic Act to establish the Center for Postmarket Evaluation and Research for Drugs and Biologics within the Food and Drug Administration (FDA). Requires the Director of the Center to conduct activities to ensure the safety and effectiveness of FDA-approved drugs and licensed biological products, including by: (1) conducting postmarket risk assessment and surveillance of such drugs and products; (2) determining whether a postmarket study is required; (3) contracting, or requiring the sponsor of such a drug or product to contract, with the holders of domestic and international patient databases to conduct epidemiologic and other observational studies; (4) determining whether a drug or product may present an unreasonable risk to the health of patients or the general public; (5) taking corrective action if such an unreasonable risk may exist; and (6) making information about the safety and effectiveness of such drugs and biological products available to the public and health care providers in a timely manner. Requires the Drug Safety and Risk Management Advisory Committee to make recommendations to the Director on postmarket studies, drugs and biological products that may present an unreasonable risk, and appropriate corrective actions. Allows the Secretary of Health and Human Services to assess civil penalties for violations of this Act. Allows the Director to withdraw or suspend approval of a drug or license for a biological product using expedited procedures under certain circumstances. Transfers to the Center the functions and duties of the Office of Surveillance and Epidemiology.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 31 January 2007

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 31 January 2007

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 31 January 2007

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 2 February 2007

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 31 January 2007

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 31 January 2007

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 31 January 2007

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.